drugs medicines may withdrawn commercial markets risks patients also commercial reasons eg lack demand relatively high production costs risks harms reason withdrawal usually prompted unexpected adverse effects detected phase iii clinical trials ie made apparent postmarketing surveillance data collected wider community longer periods time list limited drugs ever approved fda lumiracoxib rimonabant tolrestat ximelagatran ximelidine example approved marketed europe yet approved marketing us side effects became clear developers pulled market drugs list eg lsd never approved marketing us europe httpsenwikipediaorgwikilistofwithdrawndrugs